{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:06:53Z","timestamp":1793984813899,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Urotronic, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This is the first report of the 1-year outcomes of the EVEREST-I study evaluating the safety and efficacy of the Optilume<jats:sup>\u00ae<\/jats:sup> BPH Catheter System, a prostatic paclitaxel-coated balloon catheter system, for the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Subjects were men &gt;50 years old with moderate-to-severe LUTS secondary to BPH, peak urinary flow rate of 5\u201315\u2009ml\/s, prostatic urethra length 30\u201355\u2009mm, and prostate volume 20\u201380\u2009g. All were treated with the Optilume BPH Catheter System and followed at Foley removal, 2 weeks, 30 days, 3, 6, and 12 months after treatment. The primary endpoint was the proportion of subjects with \u226540% improvement in International Prostate Symptom Score (IPSS). The rate of post-procedural complications was evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty subjects were treated at six sites in Latin America and 75 completed the 1-year follow-up. The percent of subjects with an improvement \u226540% in IPSS from baseline was 81% at 3 months and 1 year. IPSS improved from 22.3 at baseline to 7.9 at 1 year, Qmax improved from 10.9 to 18.4\u2009ml\/s, and IPSS QoL improved from 4.6 to 1.3. Post-procedural complications included common urologic events and the rate of complications was significantly impacted by device diameter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment with the minimally invasive Optilume BPH Catheter System is safe and showed subjective and objective improvements in LUTS. Benefits were rapid and persisted through 1 year. The initial results warrant further evaluation of this therapy as a treatment option for patients with LUTS related to BPH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-021-00362-z","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:04:43Z","timestamp":1617883483000},"page":"1073-1079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7306","authenticated-orcid":false,"given":"Steven A.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merycarla","family":"Pichardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Rijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Espino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon Rodriguez","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"issue":"Suppl 9","key":"362_CR1","first-page":"S3","volume":"6","author":"H Lepor","year":"2004","unstructured":"Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(Suppl 9):S3\u201310.","journal-title":"Rev Urol"},{"key":"362_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1464-410x.1999.00908.x","volume":"83","author":"S Madersbacher","year":"1999","unstructured":"Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int. 1999;83:227\u201337.","journal-title":"BJU Int"},{"key":"362_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/JU.0000000000000319","volume":"202","author":"HE Foster","year":"2019","unstructured":"Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202:592\u20138.","journal-title":"J Urol"},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0090-4295(93)90335-8","volume":"42","author":"CF Donatucci","year":"1993","unstructured":"Donatucci CF, Berger N, Kreder KJ, Donohue RE, Raife MJ, Crawford ED. Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology. 1993;42:42\u201349.","journal-title":"Urology"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/pros.2990170505","volume":"3","author":"PK Reddy","year":"1990","unstructured":"Reddy PK. Role of balloon dilation in the treatment of benign prostatic hyperplasia. Prostate Suppl. 1990;3:39\u201348.","journal-title":"Prostate Suppl"},{"key":"362_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/VHRM.S81122","volume":"12","author":"M Herten","year":"2016","unstructured":"Herten M, Torsello GB, Schonefeld E, Stahlhoff S. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease. Vasc Health Risk Manag. 2016;12:341\u201356.","journal-title":"Vasc Health Risk Manag"},{"key":"362_CR7","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","volume":"154","author":"MJ Barry","year":"1995","unstructured":"Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154:1770\u20134.","journal-title":"J Urol"},{"key":"362_CR8","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190:2161\u20137.","journal-title":"J Urol"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","volume":"195","author":"KT McVary","year":"2016","unstructured":"McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529\u201338.","journal-title":"J Urol"},{"key":"362_CR10","doi-asserted-by":"publisher","first-page":"e0174586","DOI":"10.1371\/journal.pone.0174586","volume":"12","author":"W Zhang","year":"2017","unstructured":"Zhang W, Ma L, Bauer BA, Liu Z, Lu Y. Acupuncture for benign prostatic hyperplasia: a systematic review and meta-analysis. PLoS One. 2017;12:e0174586.","journal-title":"PLoS One"},{"key":"362_CR11","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11136-005-3232-x","volume":"14","author":"J Haltbakk","year":"2005","unstructured":"Haltbakk J, Hanestad BR, Hunskaar S. How important are men\u2019s lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)? Qual Life Res. 2005;14:1733\u201341.","journal-title":"Qual Life Res"}],"updated-by":[{"DOI":"10.1038\/s41391-021-00414-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00362-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:35:14Z","timestamp":1684618514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00362-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1038\/s41391-021-00362-z","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41391-021-00414-4","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-021-00414-4","URL":"https:\/\/doi.org\/10.1038\/s41391-021-00414-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SAK is the EVEREST-I principal investigator. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}